Sania Therapeutics Emerges to Advance Novel Therapies for Neural Circuit Dysfunction
Sania Therapeutics has recently emerged from stealth mode and made significant progress in the field of genetic medicines for neural circuit dysfunction. The company presented key proof-of-concept data at the ASGCT 2023 conference while introducing its proprietary patented platforms.
These innovative platforms developed by Sania Therapeutics enable precise protein delivery for neuromodulation, offering a groundbreaking approach to address neural circuit dysfunction. By harnessing adeno-associated viruses (AAV) within human neural circuits and utilizing conditionally-activated ion channels, the company aims to correct dysfunctional neural excitation. This approach holds promise for a wide range of diseases within and beyond the field of neurology.
Sania Therapeutics' technology platforms originated from the Co-Founders at the University College London. The company launched after a Series Seed financing round which allowed platform development, expanding their lead program for motor disorders, and additional undisclosed programs that utilize the technology capabilities of the platforms.
The team at Sania Therapeutics consists of world-leading scientific pioneers combined with industry drug development expertise, fostering a strong foundation for their innovative work. With their focus on developing selective medicines for neural circuit disorders, Sania Therapeutics aims to make significant contributions to the field and improve the lives of patients affected by these conditions.
